Highest-materiality recent filing
Anavex files proxy for Sep 24 meeting, adds two independent directors amid PVG proxy fight
2026 annual meeting set for Sep 24, 2026; record date Jul 31, 2026; PVG owns 0.35% of shares.
Anavex Life Sciences Announces Board Refresh, Nominates Two New Independent Directors
Nominates Gautam Patel and Dr. Adrian Senderowicz as new independent director candidates for 2026 Annual Meeting.
Anavex reports preliminary Q2 FY2026 net loss of $5.3M; cash $127.4M; focuses on FDA for Alzheimer's
Preliminary net loss $5.3M ($0.06/share) vs $11.2M ($0.13/share) in Q2 2025; R&D expenses down to $4.2M from $9.9M.
Anavex submits Nasdaq compliance plan to regain listing after late Q1 filing
Submitted compliance plan on July 20, 2026 to Nasdaq Staff regarding late Form 10-Q for March 31, 2026.
Annual meeting date set for September 24, 2026; record date for voting is July 31, 2026.
Anavex receives Nasdaq delinquency notice for late 10-Q filing; deadline July 20, 2026
Nasdaq notice received May 20, 2026 due to late Form 10-Q for quarter ended March 31, 2026.
Anavex COO Felix Lauscher departs May 11 amid reorganization after interim CEO
Felix Lauscher, COO since March 1, 2026, left Anavex on May 11, 2026.
Anavex terminates CEO Christopher Missling for cause; appoints Terrie Kellmeyer as interim CEO
Christopher Missling terminated as CEO for cause effective April 30, 2026; Board requested his resignation.
Withdrew EU marketing authorization application for blarcamesine as add-on therapy for early Alzheimer's disease.
Anavex appoints Dr. Axel Paeger to Board of Directors effective Feb 23, 2026
Dr. Paeger appointed to fill a vacancy on the board, effective February 23, 2026.
Anavex reports Q1 FY2026 net loss $5.7M; EU blarcamesine setback, re-examination ongoing
Net loss of $5.7M ($0.06 per share) vs. $12.1M ($0.14) in Q1 FY2025; R&D expenses dropped to $4.7M from $10.4M.
Net loss for Q4 fiscal 2025 was $9.8M ($0.11 per share), compared to net loss of $11.6M ($0.14) in Q4 fiscal 2024.
Anavex receives negative CHMP trend vote on blarcamesine MAA; plans re-examination
CHMP issued negative trend vote on MAA for blarcamesine for early Alzheimer's; formal opinion expected December 2025.
Anavex Life Sciences enters $150M at-the-market equity facility with TD Securities
Sales agreement with TD Securities (USA) LLC for ATM offering of up to $150M in common stock.
CEO Christopher Missling's employment term extended through July 5, 2028, with base salary $800,000 and target cash bonus of 20% of salary.
Anavex shareholders OK plan amendment to add 4M shares, enforce one-year vesting
Amendment to 2022 Omnibus Incentive Plan increases authorized shares from 10M to 14M.
Anavex terminates at-the-market equity offering agreement with Cantor Fitzgerald and SVB Securities
Terminated the Amended and Restated Sales Agreement dated May 1, 2020 effective July 24, 2024.
Anavex Life Sciences Announces Results of 2024 Annual Meeting of Stockholders
Elected six directors including Christopher Missling, PhD, with 30,256,642 for and 3,637,351 against, plus 22,413,981 broker non-votes.
Anavex Q2 FY2024 net loss $10.5M, cash $139.4M; blarcamesine EMA submission underway
Net loss of $10.5M ($0.13/share) vs $13.1M loss ($0.17/share) in prior-year quarter.
Anavex shareholders elect all six directors, ratify Grant Thornton LLP at 2023 annual meeting
65% of outstanding shares (52.1M) represented at May 23, 2023 meeting.
Anavex amends bylaws to require independent Board Chair, CEO cannot hold the role
Board of Directors adopted amended bylaws on April 11, 2023, effective immediately.
Anavex confirms no exposure to Silicon Valley Bank deposits or accounts
Company holds no deposits, securities, or accounts at Silicon Valley Bank.
Anavex files prospectus supplement for shares issuable under Lincoln Park purchase agreement
Entered Purchase Agreement with Lincoln Park Capital Fund on Feb 3, 2023.
Trial met primary endpoints ADAS-Cog and ADCS-ADL with statistically significant results (p=0.033 and p=0.0255).
Anavex shareholders approve 2022 Omnibus Incentive Plan and re-elect all six directors
All six director nominees elected with 29.3M-26.9M votes for; broker non-votes 22.8M each.
CEO Christopher Missling's employment agreement extended to July 5, 2025.
Anavex Life Sciences changes auditor from BDO to Grant Thornton LLP; no disagreements reported
Dismissed BDO as independent auditor on March 1, 2022; no adverse opinions or disagreements in prior two fiscal years.
Anavex clarifies AVATAR Phase 3 trial endpoints; plans FDA meeting for Rett syndrome approval
Anavex clarifies that the January 2022 clinicaltrials.gov update was not real-time and does not reflect late endpoint/phase changes.
Anavex Life Sciences releases data presentation via webcast; details not disclosed in filing
CEO Christopher Missling and CMO Ed Hammond presented data via webcast on February 2, 2022.
Anavex Life Sciences uplists to Nasdaq Global Select Market, ticker AVXL unchanged
Common stock approved for listing on Nasdaq Global Select Market, effective September 27, 2021.
Anavex presents at H.C. Wainwright conference; no material new information filed
Presented corporate deck at H.C. Wainwright 23rd Annual Global Investment Conference on Sep 13, 2021.
On May 11, 2026, Felix Lauscher, who had held the title of Chief Operating Officer of Anavex Life Sciences Corp. (the “Company”) since March 1, 2026, departed from the Company as part of a broader reorganization of duties at the Company following the appointment of Dr. Terrie Kellmeyer as the Company’s Interim Chief Executive Officer.
On May 4, 2026, the Board appointed Terrie Kellmeyer, PhD as the Company's Interim Chief Executive Officer.
On April 30, 2026, a special committee (the "Special Committee") composed of independent directors of the Board of Directors (the "Board") of Anavex Life Sciences Corp. (the "Company") terminated the employment of Christopher Missling, PhD as the Company's Chief Executive Officer for Cause (as defined in the Employment Agreement, dated as of June 27, 2013, between Dr. Missling and the Company, as amended and restated), effective immediately, for, among other things, conduct that the Special Committee believed was inconsistent with Company policy.
Max materiality 0.90 · Median 0.55 · Most common event other_material